1st Quarter Results

IQE PLC 22 May 2002 FOR IMMEDIATE RELEASE 22 MAY 2002 IQE plc 1st QUARTER RESULTS 2002 IQE plc (IQE), the leading global outsource supplier of customised epitaxial wafers to the semiconductor industry, is pleased to announce its 1st Quarter Results for the period ended 31 March 2002. Key Points - Q1 sales at £5.680 m, 26% less than the previous quarter and 56% lower than the first quarter of 2001 (Q1/2001: £12.959 m). - Q1 operating loss before goodwill amortisation and operating exceptional items at £4.977 m, compared with a loss of £3.795 m in the previous quarter and a profit in the first quarter of 2001 (Q1/2001: £1.264 m). - Q1 operating cash outflow held to £3.248 m, 28% less than the previous quarter due to strong cash flow management and despite higher operating losses. - Q1 capital expenditure reduced to £1.366 m, compared to £2.784 m in the previous quarter and £11.125 m in the first quarter of 2001. - Q1 additional funding of £2.897 m raised as a result of the exercise of the over-allotment option associated with the successful Placing and Open Offer of November 2001. - Strategic partnership established between IQE Silicon Compounds and AmberWave Systems Inc for the high volume manufacture of epiwafers based on their proprietary (epsilon)MOS TM strained silicon technology. The first batch of test wafers was produced in Q1 and is currently undergoing performance evaluation. A number of other customer qualification programmes were successfully completed resulting in the receipt of pilot production orders, including for SiGe products. - Continued success in new product developments particularly with Indium Phosphide HBTs. Subsequent to the quarter end IQE was able to announce that the University of California at Santa Barbara (UCSB) had achieved a record-breaking 450GHz HBT device using wafers produced by the MBE process at IQE Inc. - Commenting on the results, Dr Drew Nelson, President and CEO, said... .... 'Although the markets in which we operate weakened still further in the quarter and trading remained very difficult, we were able to successfully conserve our cash resources and strengthen our position as a technology leader in our industry. This is clearly demonstrated by the strategic partnership with AmberWave Systems Inc., on strained silicon technology and the record-breaking results achieved with our InP HBT material. Our balance sheet remains strong and we are continuing to keep a tight control on costs. We have continued to develop a product portfolio which addresses a much wider end-user market than previously, and we believe IQE is well placed to consolidate its position as the world's leading global outsource supplier of customised epitaxial wafers as the market returns across the various semiconductor sectors. We are now beginning to see some improvements in trading and, in line with previous guidance, expect H1 to be the bottom of the current downturn for us' For further information please contact: Drew Nelson, President and CEO, IQE plc (029)20-839400 Richard Clarke, Finance Director, IQE plc (029)20-839400 Tim Thompson/Nicola Cronk, Buchanan Communications (020)74-665000 INTRODUCTION Q1 2002 proved to be an extremely difficult trading period as we had indicated in our full year results announcement. There were initially some indications of recovery in the wireless electronics market in Q4 2001, but this was not sustained in Q1 2002 as the first quarter is traditionally weak in this market sector. There was also further deterioration in the opto-electronics market where the component manufacturers, who are the Company's main customers in this sector, continued to be impacted by low levels of capital expenditure by end users. In addition to very low production volumes, new product development programmes have also been scaled back or delayed. However, there have been some encouraging increases in order intake in the UK and US epiwafer operations since the end of the quarter, and we expect H1 to represent the bottom of the current downturn for the Group. RESULTS Q1 sales were £5.680 m, 26% less than the preceding quarter and 56% lower than the first quarter of the previous year (Q1/2001: £12.959 m) in line with previous guidance. This was as a result of continued very low production volumes of opto-electronic products in Q1 combined with a marked further slowdown in customer funded new development programmes and some contract slippage into Q2. The market for indium phosphide substrates at Wafer Technology remained extremely weak, although partially offset by some recovery in the demand for lower margin gallium arsenide LED substrates and sustained orders for antimonide substrates. The high level of operational gearing, particularly in the UK and US III-V operations, meant that gross margins deteriorated further in Q1 to -21.4% (Q4/2001: -1.3%) principally due to lower capacity utilisation. The US operation continued to be affected by weaker sales margins and was adversely impacted by higher than expected equipment maintenance costs. Overall margins at Wafer Technology were lower due to the higher proportion of lower margin GaAs LED substrates shipped in the quarter. Q1 research and development costs were £1.142 m, representing a record 20.1% of sales (Q4/2001: £0.894 m, 11.6% of sales), and were focussed on a range of new products including InP HBTs. Since the quarter end, IQE has been able to announce that the University of California at Santa Barbara (UCSB) had achieved a record-breaking 450GHz HBT device using wafers produced by the MBE process at IQE Inc. Other key areas of development included long wavelength VCSELs and Avalanche Photodiodes (APDs), as well as the GaAs on Silicon technology in partnership with Motorola and the strained silicon technology in conjunction with AmberWave. All research and development expenditure was expensed in the quarter as incurred. SG&A expenses at £2.620 m were lower than in the previous quarter (Q4/2001: £2.800 m), which was impacted by increases in provisions for doubtful debts, but remained at a high level largely due to high sales and marketing costs. As a result of the above, the Group incurred a Q1 operating loss before goodwill amortisation and operating exceptional items of £4.977 m, compared with a loss in the previous quarter of £3.795 m and a profit in the first quarter of 2001 (Q1/2001: £1.264 m). This represents an operating margin of -87.6% as against 9.8% for last year. The operating loss before tax was £5.771 m (Q1/2001: profit £1.100 m) after charging net interest costs of £0.012 m (Q1/2001: net interest income £0.295 m) ; operating exceptional items of £0.345 m (Q1/2001: Nil) ; and goodwill amortisation relating to the Wafer Technology acquisition of £0.437 m (Q1/2001: £0.459 m). No tax credit has been recognised as it is not the Group's policy to recognise deferred tax assets, so the after tax loss was also £5.771 m (Q1/2001: profit of £0.581 m) and the basic loss per share was 3.13 pence (Q1/2001: earnings per share of 0.36 pence). Excluding goodwill amortisation, the loss per share remains at 3.13 pence (Q1/2001: earnings per share of 0.34 pence). The Group incurred an operating cash outflow in Q1 of £3.248 m (Q1/2001: inflow of £1.397 m) as a result of operating losses and a further reduction in creditors, which more than offset continuing reductions in debtors and stocks. The cash outflow was 28% less than the previous quarter (Q4/2001: outflow of £4.516 m) despite increased operating losses. Capital expenditure, which had reduced substantially in the second half of 2001, was further reduced in Q1 to only £1.366 m (Q1/2001: £11.125 m) and was less than half the previous quarter (Q4/2001: £2.784 m). The net cash outflow for Q1 before financing was £4.626 m (Q1/2001: £9.293 m). This reduced to £2.614 m as a result of the additional funds raised in the quarter through the exercise of the over-allotment option associated with the successful Placing and Open Offer in December last year. OPERATIONS The Group was adversely affected during Q1 by a combination of seasonal weakness in the wireless markets; stretching of new development contracts and a further decline in production orders from opto-electronic manufacturers, who continue to suffer from low demand and excess inventories as end user capital expenditure has continued to fall. The headcount in the UK epiwafer operation was reduced by 30 early in the quarter and other cost saving initiatives were introduced in order to reduce costs and conserve cash. However, considerable progress was again made in new product developments for next generation systems, particularly in Indium Phosphide HBTs and APDs for next generation 40 Gbits/systems, InGaP HBTs for wireless applications, strained silicon technology for high performance ICs and Three Five on Silicon (TFOS) technology. There were definite signs of improvement in trading conditions in the wireless market in Q4 2001 with some significant production orders agreed with customers but the upturn remained patchy in Q1, which is traditionally the weakest quarter. We have experienced a strengthening of this market since the end of the quarter and clear signs of a pick up are now evident. New product development activity continues to be successful, with the Group's InP HBT wafers now designed into several new customer products and record breaking results announced using IQE wafers. Further progress continues to be made in development of the Three Five on Silicon Technology and the first early adopter customers have now been signed up. Strong dialogue continues with several other parties to identify the key products of major interest and benefit to the customer base in order to effectively target the technology to maximum effect. Wafer Technology continues to perform well on specialist wafer products, although their more mature business has suffered as a consequence of the very difficult market conditions. Q1 continued to see recovery in gallium arsenide substrates, particularly for LED products, but this was more than offset by a reduction in indium phosphide product which also had a negative margin impact. Strong demand for antimonide products was experienced towards the end of the quarter and a small degree of visibility is now becoming apparent. There has continued to be strong progress at IQE Silicon Compounds. A number of qualification programmes have now successfully completed and as a result the company has been running pre-production orders for some large European IC manufacturers. Major progress was made with the signing of a strategic partnership with AmberWave Systems Inc for high volume manufacture of epiwafers based on their proprietary (epsilon)MOSTM strained silicon technology. Strained silicon has been identified as a potentially powerful solution to overcome the physical speed limitations presented by the material properties of elemental silicon and offers the silicon industry immediate and cost effective access to epiwafers that will increase speed and reduce power in conventional CMOS, facilitating substantial advancements in digital, wireless and opto-electronic applications. IQE SC became the first licensee of this technology and during the quarter shipped a number of wafers for product qualification. BOARD CHANGES Following recent Board announcements which saw the appointments of Dr Godfrey Ainsworth as Non Executive Chairman and Mr Simon Gibson OBE as Non Executive Director, the Group intends to further strengthen its Board with the appointment of two further Non Executive Directors. The number of Executive Directors on the main Board will also be substantially reduced in line with corporate governance guidelines through the formation of a separate Executive Board of the Company. TRADING PROSPECTS Since the end of the first quarter, we have begun to experience a pick up in order activity, with a positive book to bill for the last 6 weeks, particularly in the wireless sector. We therefore re iterate our belief that H1 will most likely represent the bottom of the current downturn for us and we should see sequential increases in revenue and bottom line performance, particularly in the second half of the year. The Board continues to believe that as the semiconductor industry recovers, together with the exceptionally exciting medium and longer term opportunities open to the Group as a result of its agreements with AmberWave Systems Inc., and Motorola and with outsourcing becoming a much more prominent part of the compound semiconductor industry, IQE is well placed to consolidate its position as the leading global outsource wafer manufacturer within the semiconductor industry. Dr Drew Nelson President and Chief Executive Officer IQE plc PROFIT AND LOSS ACCOUNT 3 months 3 months 12 months to to to Note 31 Mar 31 Mar 31 Dec 2002 2001 2001 (All figures GBP000s) unaudited unaudited audited Turnover 5,680 12,959 42,047 Cost of Sales (6,895) (8,571) (32,381) Gross Profit (1,215) 4,388 9,666 Gross Profit % (21.4) 33.9 23.0 S G and A Costs : Research/Development (1,142) (539) (3,792) Selling/General/Administration (2,620) (2,585) (9,341) Operating Profit/(Loss) before Goodwill/Exceptionals (4,977) 1,264 (3,467) Operating Profit/(Loss) % before Goodwill/Exceptionals (87.6) 9.8 (8.2) Goodwill Written off 2 (437) (459) (1,835) Exceptional Items 3 (345) (0) (759) Operating Profit/(Loss) after Goodwill/Exceptionals (5,759) 805 (6,061) Operating Profit/(Loss) % after Goodwill/Exceptionals (101.4) 6.2 (14.4) Interest Received/(Paid) (12) 295 211 Net Profit/(Loss) before Taxes (5,771) 1,100 (5,850) Net Profit/(Loss) % (101.6) 8.5 (13.9) Current Taxes (0) (519) (103) Deferred Taxes (0) (0) 373 Dividends (0) (0) (0) Net Profit/(Loss) after Taxes (5,771) 581 (5,580) Basic Earnings Pence/Share (3.13) 0.36 (3.38) Basic Earnings Pence/Share excl Goodwill (2.90) 0.64 (2.27) Diluted Earnings Pence/Share 5 (3.13) 0.34 (3.38) Diluted Earnings Pence/Share excl Goodwill 5 (2.90) 0.60 (2.27) Net Profit/(Loss) before Interest/Taxes/ Depreciation and Amortization (EBITDA) (3,396) 2,591 2,196 BALANCE SHEET As At As At As At 31 Mar 2002 31 Mar 2001 31 Dec 2001 (All figures GBP000s) unaudited unaudited audited Fixed Assets : Intangible Fixed Assets 33,866 36,084 34,658 Tangible Fixed Assets 74,772 58,198 74,193 Investment in Own Shares 3 0 3 Capitalized Research and Development 0 250 0 Total Fixed Assets 108,640 94,531 108,854 Current Assets : Stocks 10,644 10,283 12,277 Debtors 6,589 12,890 7,495 Cash and Bank 27,918 31,223 30,532 Total Current Assets 45,150 54,396 50,304 Creditors Falling Due within One Year (9,404) (21,396) (11,945) Net Current Assets 35,746 33,000 38,359 Total Assets less Current Liabilities 144,386 127,531 147,213 Creditors Falling Due after One Year : Deferred Income (141) (63) (173) Deferred Tax Liability (1,215) (1,590) (1,217) Long Term Borrowings (7,773) (6,899) (8,211) Net Assets 135,256 118,978 137,612 Capital and Reserves : Called Up Share Capital 1,851 1,635 1,824 Merger Reserve (605) (605) (605) Share Premium Account 140,162 111,854 136,661 Shares to be Issued 0 988 938 Retained Earnings (8,261) 3,671 (2,490) Other Reserves 2,110 1,436 1,284 Total Equity Shareholders' Funds 135,256 118,978 137,612 CASH FLOW STATEMENT 3 months to 3 months to 12 months to 31 Mar 2002 31 Mar 2001 31 Dec 2001 (All figures GBP000s) unaudited unaudited audited Net Inflow/(Outflow) from Operations (3,248) 1,397 (7,066) Returns on Investment and Servicing Finance : Interest Received/(Paid) (12) 295 211 Capital Expenditures : Purchases of Fixed Assets less Leases (1,366) (11,125) (25,169) Received Payments to Acquire Investments in 0 0 0 Subsidiaries Capitalized Development Costs (0) (250) 0 Dividends Received/(Paid) 0 0 0 Taxes Received/(Paid) 0 391 322 Net Inflow/(Outflow) before Financing (4,626) (9,293) (31,702) Financing : Issues of Ordinary Share Capital 2,897 53 25,049 Loans Received/(Repaid) (277) 975 (463) Leases (Repaid) (609) (24) (1,863) Net Inflow/(Outflow) from Financing 2,011 1,004 22,723 Increase/(Decrease) in Cash and Bank Overdrafts (2,614) (8,289) (8,979) RECONCILIATION OF PROFIT TO CASH INFLOW/(OUTFLOW) FROM OPERATIONS 3 months to 3 months to 12 months to 31 Mar 2002 31 Mar 2001 31 Dec 2001 (All figures GBP000s) unaudited unaudited audited Operating Profit after Goodwill/Exceptionals (5,759) 805 (6,061) Depreciation Charged 1,926 1,327 6,422 Goodwill Written off 437 459 1,836 (Gain)/Loss on Sale of Fixed Assets 0 0 0 (Increase)/Decrease in Stocks 1,633 (2,398) (4,392) (Increase)/Decrease in Debtors 906 (2,579) 2,882 Increase/(Decrease) in Creditors (2,359) 3,788 (7,857) Grants Released (32) (6) (504) Grants Received 0 0 608 Net Cash Inflow/(Outflow) from Operations (3,248) 1,397 (7,066) RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS 3 months to 3 months to 12 months to 31 Mar 2002 31 Mar 2001 31 Dec 2001 (All figures GBP000s) unaudited unaudited audited Increase/(Decrease) in Cash (2,614) (8,289) (8,979) Loans (Received)/Repaid 277 (975) 463 Leases Repaid 609 24 1,863 Change in Funds Resulting from Cash Flows (1,728) (9,240) (6,653) New Finance Leases (376) (0) (7,054) Net Movement (2,104) (9,240) (13,707) Net Funds at Start 19,104 32,813 32,813 Exchange Differences 0 (92) (2) Net Funds at Close 17,000 23,481 19,104 Analysis of Net Funds : Cash and Bank 27,918 31,223 30,532 Debt Due after One Year (2,640) (3,804) (2,899) Debt Due within One Year (656) (574) (674) HP Creditors/Finance Leases (7,622) (3,364) (7,855) Total 17,000 23,481 19,104 RECONCILIATION OF UKGAAP TO IAS 3 months to 3 months to 12 months to 31 Mar 2002 31 Mar 2001 31 Dec 2001 (All figures GBP000s) unaudited unaudited audited (1) Statement of Cash Flows The following shows the statement of cash flows as if they had been presented under IAS Cash Inflow/(Outflow) from Operations (3,247) 1,788 (6,744) Cash Inflow/(Outflow) from Investing (1,378) (11,080) (24,958) Cash Inflow/(Outflow) from Financing 2,011 1,004 22,723 Net Increase/(Decrease) in Cash and Cash Equivalents (2,614) (8,289) (8,979) Opening Cash and Cash Equivalents per IAS 30,533 39,512 39,512 Exchange Difference 0 0 0 Closing Cash and Cash Equivalents per IAS 27,919 31,223 30,533 (2) Goodwill Goodwill of £284,000 arose on acquisition of IQE (Europe) by EPIH on 27 March 1996. Under UK GAAP, this has been written off directly to reserves. Under IAS, however, goodwill arising on acquisition should be recognized as an asset and amortized over its useful life. The following shows the retained profit and total net assets as if they had been prepared under IAS with goodwill amortized over 5 years. Profit/(Loss) after Taxes and Exceptionals (5,771) 581 (5,580) Dividends (0) (0) (0) Retained Profit/(Loss) per UK GAAP (5,771) 581 (5,580) Goodwill Amortization (14) (14) (57) Retained Profit/(Loss) per IAS (5,785) 567 (5,637) Equity Shareholders' Funds per UK GAAP 135,256 118,978 137,612 Goodwill Capitalization at Cost 284 284 284 Accumulated Goodwill Amortization (284) (227) (270) Equity Shareholders' Funds per IAS 135,256 119,035 137,626 NOTES TO THE ACCOUNTS 1 BASIS OF PREPARATION The financial information is prepared under the historical cost convention and in accordance with applicable accounting standards, which have been applied on a consistent basis during the period under review. The particular accounting policies adopted are described below : * Turnover represents amounts invoiced exclusive of value added taxation. * Tangible fixed assets are stated at cost less accumulated depreciation. Cost comprises all costs that are directly attributable to bringing the asset into working condition for its intended use, as defined by Financial Reporting Standard Number 15. Depreciation has been calculated so as to write down the cost of assets to their residual values over the following estimated useful economic lives. No depreciation is provided on land or assets in the course of construction. Freehold buildings 25 years Short leasehold improvements 5/27 years Plant and machinery 5/7 years Fixtures and fittings 4/5 years Motor vehicles 4 years * The financial information consolidates the financial statements of the Company and all of its subsidiaries. The acquisition of IQE (Europe) Limited (formerly known as Epitaxial Products International Limited) and its subsidiary Epitaxial Products Inc on 27 March 1996 by EPI Holdings Limited, a new company established for that purpose, has been accounted for under acquisition accounting, whereby these Companies became part of the Group on the date of acquisition. The acquisition of EPI Holdings Limited and IQE Inc (formerly Quantum Epitaxial Designs Inc) on 16 May 1999 by IQE plc, a new holding company established for that purpose, has been accounted for under merger accounting, whereby the financial information is disclosed as if the companies had always been part of the same Group. The acquisition of Wafer Technology International Limited and its subsidiary Wafer Technology Limited on 22 November 2000 by IQE plc has been accounted for under acquisition accounting, whereby these companies became part of the Group on the date of acquisition. * Stocks are stated at the lower of cost and net realizable value. * Research and development expenditure is fully written off when incurred except where contracts of sufficient value exist or are likely to exist in the foreseeable future, and are written off over a two year period commencing with the start of the contracts to which the costs relate. * Transactions in foreign currencies during the period are recorded in sterling at the rates ruling at the dates of the transactions. Monetary assets and liabilities in foreign currencies are translated into sterling at the rates ruling at the balance sheet date. All exchange differences are taken to the profit and loss account. The balance sheets of IQE Inc (formerly Quantum Epitaxial Designs Inc) are translated into sterling at the closing rates of exchange for the period, while the profit and loss accounts are translated into sterling at the average rates of exchange for the period. The resulting translation differences are taken direct to reserves. * The Group operates a defined contribution pension scheme. Contributions are charged in the profit and loss account as they become payable in accordance with the rules of the scheme. * Deferred taxation is provided on timing differences, arising from the different treatment of items for accounting and taxation purposes, which are expected to reverse in the future without replacement, calculated at the rates at which it is expected that tax will arise. * Government grants receivable in connection with expenditure on tangible fixed assets are accounted for as deferred income, which is credited to the profit and loss account by instalments over the expected useful economic life of the related assets on a basis consistent with the depreciation policy. Revenue grants for the reimbursement of costs incurred are deducted from the costs to which they related, in the period in which the costs are incurred. * Assets held under finance leases and hire purchase contracts are capitalized at their fair value on inception of the leases and depreciated over the shorter of the period of the lease and the estimated useful economic lives of the assets. The finance charges are allocated over the period of the lease in proportion to the capital amount outstanding and are charged to the profit and loss account. Operating lease rentals are charged to the profit and loss account in equal amounts over the lease term. * The only derivative instruments utilized by the Group are forward exchange contracts. The Group does not enter into speculative derivative contracts. Forward exchange contracts are used for hedging purposes to alter the risk profile of an existing underlying exposure of the Group in line with the Group's risk management policies. 2 GOODWILL On the acquisition of a business, fair values are attributed to the Group's share of the net tangible assets acquired. Where the cost of the acquisition exceeds the values attributable to such net assets, the difference is treated as purchased goodwill. The goodwill arising on the acquisition of IQE (Europe) Limited (formerly Epitaxial Products International Limited) and its subsidiary Epitaxial Products Inc by EPI Holdings Limited was written off directly to reserves in the year of acquisition. Goodwill of £284,000 remains eliminated in the profit and loss reserve and will be charged to the profit and loss account on the subsequent disposal of IQE (Europe) Limited and Epitaxial Products Inc. Following the issue of Financial Reporting Standard 10, goodwill arising in accounting periods ending on or after 23 December 1998 must be classified as an asset on the balance sheet and amortized over its useful life The goodwill arising on the acquisition of Wafer Technology International Limited and its subsidiary Wafer Technology Limited has been capitalized and is being amortized over its useful life, which is considered by the Directors to be 20 years. 3 EXCEPTIONAL ITEMS 2002 2001 Exceptional items comprise : Legal fees £345K £0K Legal fees relate to a complaint lodged by IQE (Europe) against Rockwell regarding a declaratory judgment that IQE Europe's processes did not infringe a Rockwell-owned MOCVD patent which expired on 11 January 2000 plus claims for damages related to this matter. There is a counter claim by Rockwell alleging breaches of a licence agreement by IQE (Europe). Two legal opinions obtained by IQE (Europe) in the US clearly support IQE's view that its processes were not covered by Rockwell's patent, the validity of which is separately being disputed by other companies in the US. It is uncertain whether the matter will ultimately go to trial or what the outcome will be. 4 CONTINGENT LIABILITY A claim has been made against the Group alleging breaches of a licence agreement. The Group is vigorously defending this action and at this stage the outcome is uncertain. Due to the uncertainty of the outcome it is not possible to conclude as to whether a probable transfer of economic benefits will be required to settle any obligation, nor can a reliable estimate be made of the amount of such an obligation should such an obligation result from the claim. Accordingly, under the provisions of FRS 13, no provision has been made in the accounts for any potential future liability that may arise from the claim. As discussed in note 3, the Group has expensed in the year legal fees totalling £345,000 in respect of defending this claim. In the view of the Directors, the Group may incur further legal costs of up to £700,000 in the year ended 31 December 2002 should this legal action continue. 5 EARNINGS PER SHARE FRS 14 requires the presentation of diluted EPS when a company could be called upon to issue shares that would decrease net profit or increase net loss per share. For a loss making company with outstanding share options, net loss per share would only be increased by the exercise of the out of the money options. Since it seems inappropriate to assume that options holders would act irrationally, no adjustment has been made to diluted EPS for out of the money share options. This information is provided by RNS The company news service from the London Stock Exchange

Companies

IQE (IQE)
UK 100

Latest directors dealings